What Researchers Did
Researchers reviewed existing studies to understand the scientific reasons and available clinical evidence for using hyperbaric oxygen therapy (HBOT) to treat complications of sickle cell disease.
What They Found
The review found that current evidence for HBOT in sickle cell disease complications comes from limited studies, such as case reports, small patient series, and early-phase studies with varying treatment methods. These early findings suggest that HBOT may improve pain control and help with tissue healing in some patients, and it appears generally well tolerated.
What This Means for Canadian Patients
For Canadian patients living with sickle cell disease, HBOT could potentially offer a new approach to manage difficult complications like bone disease, chronic leg ulcers, or eye problems. However, more robust research is needed to confirm its effectiveness and establish clear guidelines for its use in this population.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The review's findings are limited because they are based on a small number of early-stage studies, case reports, and studies using different treatment approaches, meaning definitive conclusions cannot yet be drawn.